Pfizer Stock Drops 2.5%, Traders Bearish Despite Metastatic Breast Cancer Progress

PFE shares fell 2.52% on April 7, 2026, as RBC Capital reiterated an Underperform rating with a $25 price target, citing mounting product headwinds across three of Pfizer's key revenue pillars. Paxlovid faces ongoing demand erosion as pandemic-era prescribing normalizes, Vyndamax has experienced gross pricing pressure for six consecutive quarters as cardiology competition intensifies, and Prevnar faces an accelerating challenge from Merck's Capvaxive in the vaccine segment. RBC projects Q1 2026 revenues approximately 4% below consensus.

The negative price action came on the same day Pfizer highlighted progress in its CDK inhibitor pipeline for metastatic breast cancer — specifically atirmociclib, its investigational CDK4-selective compound — which showed a 32% objective response rate in Phase 1/2 trials in heavily pretreated patients. While the pipeline news signals long-term research momentum, markets chose to discount it in favor of near-term revenue concerns, a pattern that has become familiar for PFE as it navigates the post-Paxlovid revenue cliff.

The broader dynamic reflects a persistent tension in large-cap pharma investing: early-stage pipeline wins rarely offset visible near-term headwinds in market sentiment. With option traders positioning bearishly and analyst coverage skewing negative, Pfizer's next catalyst is the Q1 earnings report — where investors will look for signs that Vyndamax pricing erosion is stabilizing and that Prevnar's new contract cycle can partially offset Capvaxive's inroads.